• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    GT Biopharma Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Financial Statements and Exhibits

    9/23/25 5:30:50 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GTBP alert in real time by email
    false 0000109657 0000109657 2025-09-17 2025-09-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

     

    Date of Report: September 17, 2025

    (Date of earliest event reported)

     

     

     

    GT Biopharma, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    (State or other Jurisdiction

    of Incorporation)

     

    1-40023   94-1620407

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    N/A1

    (Address of Principal Executive Offices and zip code)

     

    (415) 919-4040

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each Class   Trading Symbol(s)   Name of each Exchange on which registered
    Common stock, $0.001 par value   GTBP   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

    1 Effective as of July 1, 2024, the Company became a fully remote company. We do not maintain a principal executive office. For purposes of compliance with applicable requirements of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, any stockholder communication required to be sent to the Company’s principal executive offices may be directed to 505 Montgomery Street, 10th Floor, San Francisco, California 94111, or by email to [email protected].

     

     

     

     

     

     

    Item 3.03 Material Modification to Rights of Security Holders.

     

    On each of September 17, 2025, September 18, 2025 and September 23, 2025, certain of the holders of GT Biopharma, Inc.’s Series L 10% Convertible Preferred Stock (the “Series L Preferred Stock”) provided a waiver (the “Waiver”) to the Certificate of Designation of Preferences, Rights and Limitations of Series L 10% Convertible Preferred Stock (the “Certificate of Designations”). Pursuant to the Waiver, such Series L Preferred Stockholders agreed to waive the rights to redemption set forth in Section 10 of the Certificate of Designations.

     

    The foregoing description of the Waiver does not purport to be complete and is qualified in its entirety by reference to the full text of the Waiver, which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit Number   Description
    10.1   Form of Waiver
         
    104   Cover Page Interactive Data File, formatted in Inline XBRL

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      GT BIOPHARMA, INC.
       
    Date: September 23, 2025 By: /s/ Alan Urban
        Alan Urban
        Chief Financial Officer

     

     

    Get the next $GTBP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GTBP

    DatePrice TargetRatingAnalyst
    12/2/2024$11.00Buy
    ROTH MKM
    More analyst ratings

    $GTBP
    SEC Filings

    View All

    GT Biopharma Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Financial Statements and Exhibits

    8-K - GT Biopharma, Inc. (0000109657) (Filer)

    9/26/25 4:15:54 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GT Biopharma Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Financial Statements and Exhibits

    8-K - GT Biopharma, Inc. (0000109657) (Filer)

    9/23/25 5:30:50 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GT Biopharma Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - GT Biopharma, Inc. (0000109657) (Filer)

    8/29/25 4:15:35 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GTBP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on GT Biopharma with a new price target

    ROTH MKM initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $11.00

    12/2/24 10:00:20 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on GT Biopharma with a new price target

    HC Wainwright & Co. initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $25.00

    5/24/21 6:11:36 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on GT Biopharma with a new price target

    B. Riley Securities initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $21.00

    4/13/21 6:45:30 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GTBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Mun-Gavin David C.

    4 - GT Biopharma, Inc. (0000109657) (Issuer)

    9/8/25 5:45:44 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO and Director Breen Michael Martin

    4 - GT Biopharma, Inc. (0000109657) (Issuer)

    9/8/25 5:45:43 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Casamento Charles J

    4 - GT Biopharma, Inc. (0000109657) (Issuer)

    9/8/25 5:45:40 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GTBP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

    Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity Insider News Commentary – MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more effectively destroy cancer, opening doors to off-the-shelf treatments doctors can administer immediately after diagnosis instead of waiting weeks for personalized cell production[1]. Eight new oncology approvals between July and September 2025 demonstrate how cellular immunotherapy platforms are solving manufacturing challenges while expanding from blood cancers into solid tumors, with researchers discovering ways to reprogram immune cell

    10/17/25 9:50:00 AM ET
    $EDAP
    $EVAX
    $GTBP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Pharmaceutical Preparations

    Next-Generation Targeted Therapies Reshape Precision Oncology Landscape

    USA News Group News Commentary –Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 15, 2025 /PRNewswire/ -- USA News Group News Commentary – Biomarker-driven drug development is accelerating across oncology as companies advance novel mechanisms targeting previously difficult-to-treat patient populations. The cancer immunotherapy market reached $226 billion in 2024 and continues expanding rapidly, driven by precision approaches that pair targeted agents with immunotherapy, identify genetic vulnerabilities, and deploy radioligand therapies for metastatic disease[1]. Recent clinical data demonstrating high response rates in biomarker-selected populations underscore the shift toward mole

    10/15/25 9:11:00 AM ET
    $GTBP
    $IDYA
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge

    Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 15, 2025 /PRNewswire/ -- Eight new oncology approvals between July and September 2025 marked a pivotal quarter for cancer treatment[1], as cellular immunotherapy platforms continue redefining treatment paradigms for hematologic malignancies and expanding into solid tumors[2]. Recent innovations including CAR-NK cells, CAR-Treg cells, and in vivo CAR-T approaches are solving manufacturing challenges[3] while outpatient CAR-T centers now deliver advanced therapies that previously required lengthy hospital stays[4]. Alternative drug delivery methods and targeted therapy approvals for lung cancer, breast ca

    10/15/25 8:45:00 AM ET
    $GDTC
    $GTBP
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Medical/Dental Instruments

    $GTBP
    Financials

    Live finance-specific insights

    View All

    Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

    Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity Insider News Commentary – MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more effectively destroy cancer, opening doors to off-the-shelf treatments doctors can administer immediately after diagnosis instead of waiting weeks for personalized cell production[1]. Eight new oncology approvals between July and September 2025 demonstrate how cellular immunotherapy platforms are solving manufacturing challenges while expanding from blood cancers into solid tumors, with researchers discovering ways to reprogram immune cell

    10/17/25 9:50:00 AM ET
    $EDAP
    $EVAX
    $GTBP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Pharmaceutical Preparations

    Peter Derycz and Bristol Investment Fund Ltd. Issue Open Letter to Research Solutions, Inc. Shareholders

    Believe Urgent Change is Needed at Research Solutions to Address Underperformance, Poor Operational Execution, and Lack of Accountability Highlight that Since Roy Olivier Became Chief Executive Officer, Research Solutions' Share Price Has Declined More than 20% THOUSAND OAKS, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Peter Derycz, Bristol Investment Fund Ltd. ("Bristol Fund") and certain of Bristol Fund's affiliates (collectively, the "Group"), who collectively beneficially own approximately 20% of Research Solutions, Inc.'s (NASDAQ:RSSS) outstanding shares, today issued an open letter from Mr. Derycz to RSSS shareholders regarding why change is needed at RSSS and the Group's intention t

    8/4/23 9:30:41 AM ET
    $GTBP
    $RSSS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    EDP Services
    Technology

    GT BioPharma to Host a Management Update Conference Call

    BEVERLY HILLS, Calif., Nov. 24, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that Michael Breen, Executive Chairman and Dr. Greg Berk, President of R&D, Chief Medical Officer and Interim Chief Executive Officer will be hosting a Management Update Conference call on Tuesday, November 30th at 4:30PM Eastern Time. To join the live webcast of the call and view the accom

    11/24/21 4:05:00 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GTBP
    Leadership Updates

    Live Leadership Updates

    View All

    GT Biopharma Appoints New Member to its Board of Directors

    SAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of David C. Mun-Gavin to its Board of Directors. "We are very pleased to welcome David to the Board of Directors. David is an experienced senior executive with global connections and a proven track record of success in working with corporate management teams," said Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma. "His guidance and perspective will be

    6/13/25 9:00:00 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GT Biopharma Appoints New Member to its Board of Directors

    SAN FRANCISCO, CALIFORNIA, May 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of Hilary Kramer to its Board of Directors. Mrs. Kramer will be replacing current board member Bruce Wendel, who is resigning his position. "We are delighted to welcome Hilary to the Board of Directors at this exciting time, and we look forward to leveraging her expertise as we continue to make great clinical progress with our NK engagers," said Michael Breen, Executive Chairman a

    5/14/25 7:00:00 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GT Biopharma Appoints Manu Ohri as Chief Financial Officer

    BRISBANE, Calif., Feb. 18, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced the appointment of Manu Ohri, who joins the Company as its Chief Financial Officer (CFO) effective immediately. Mr. Ohri, an accomplished accounting and finance executive brings to GT Biopharma over 25 years of management, finance and public accounting experience in working with Boar

    2/18/22 7:30:00 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GTBP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by GT Biopharma Inc. (Amendment)

    SC 13G/A - GT Biopharma, Inc. (0000109657) (Subject)

    5/23/24 8:31:08 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by GT Biopharma Inc. (Amendment)

    SC 13G/A - GT Biopharma, Inc. (0000109657) (Subject)

    2/14/24 2:46:25 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by GT Biopharma Inc.

    SC 13G - GT Biopharma, Inc. (0000109657) (Subject)

    9/19/23 11:56:06 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care